研究人員正在尋找治療某些類型晚期胃腸道（GI）癌症的新方法。研究藥物 raludotatug deruxtecan（亦稱 MK-5909、R-DXd 或 DS-6000a）是一種稱為抗體藥物偶聯物（ADC）的藥物。ADC 會附著於癌細胞上的蛋白，並傳遞治療以摧毀這些細胞。 本研究的主要目標是了解癌症是否對治療產生反應（縮小或消失）。
適應症：Gastrointestinal Cancer
收案條件
納入條件
- Has one of the following cancers:
- Unresectable or metastatic pancreatic ductal adenocarcinoma (PDAC)
- Unresectable or metastatic adenocarcinoma of the biliary tract \[intra- or extrahepatic holangiocarcinoma (CCA) or gallbladder cancer (GBC)\]
- Unresectable or metastatic colorectal adenocarcinoma
- Unresectable or metastatic gastric adenocarcinoma
- Gastroesophageal junction adenocarcinoma (GEJAC)
- Esophageal adenocarcinoma (EAC)
- Has received prior therapy for the cancer
- Has a life expectancy of at least 3 months
- If human immunodeficiency virus (HIV) infected, must have well controlled HIV on antiretroviral therapy (ART)
排除條件
- Has a history of (noninfectious) interstitial lung disease (ILD)/pneumonitis that required steroids or has current ILD/pneumonitis, and/or suspected ILD/pneumonitis
- Has clinically severe pulmonary compromise resulting from intercurrent pulmonary illnesses
- Has uncontrolled or significant cardiovascular disease
- Has a known additional malignancy that is progressing or has required active treatment within the past 3 years
- Has known active central nervous system (CNS) metastases and/or carcinomatous meningitis
- Active autoimmune disease that has required systemic treatment in the past 2 years
- Has not adequately recovered from major surgery or has ongoing surgical complications
- HIV-infected participants with a history of Kaposi's sarcoma and/or Multicentric Castleman's Disease
收案條件維持 ClinicalTrials.gov 原始英文登錄資料，實際收案資格以研究團隊的正式評估與受試者同意書為準。資料來源：ClinicalTrials.gov，每兩週自動更新，最後同步：2026年10月8日。